Syra Health Corp. Class A Common StockSYRANASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank7
Year-over-Year Change
Year-over-year research & development expense growth
Latest
-97.25%
↓ 379% vs avg
Percentile
P7
Near historical low
Streak
2 qtr
Consecutive declineDecelerating
Average
34.85%
Historical baseline
| Period | Value |
|---|---|
| Q3 2025 | -97.25% |
| Q2 2025 | -20.07% |
| Q1 2025 | 826.46% |
| Q4 2024 | -114.70% |
| Q3 2024 | -87.47% |
| Q2 2024 | 0.12% |
| Q1 2024 | 15.62% |
| Q4 2023 | 0.00% |
| Q3 2023 | 0.00% |
| Q2 2023 | 0.00% |
| Q1 2023 | 0.00% |
| Q4 2022 | 0.00% |
| Q3 2022 | 0.00% |
| Q2 2022 | 0.00% |
| Q1 2022 | 0.00% |